VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.45%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$243M
AUM Growth
+$6.44M
(+2.7%)
Cap. Flow
-$3.44M
Cap. Flow
% of AUM
-1.41%
Top 10 Holdings %
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11
Top Buys
| 1 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
$670K |
| 2 |
Zai Lab
ZLAB
|
$520K |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$422K |
| 4 |
DRD
DRDGold
DRD
|
$405K |
| 5 |
Stellus Capital Investment Corp
SCM
|
$402K |
Top Sells
| 1 |
AMRS
Amyris Inc.
AMRS
|
$1.28M |
| 2 |
Prothena Corp
PRTA
|
$971K |
| 3 |
BioNTech
BNTX
|
$787K |
| 4 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
$647K |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$645K |
Sector Composition
| 1 | Healthcare | 27.38% |
| 2 | Real Estate | 18.81% |
| 3 | Energy | 13.29% |
| 4 | Materials | 10.7% |
| 5 | Utilities | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Gossamer Bio
GOSS
$668M
| $206K | 0.08% |
25,361
-3,102
| -11% | -$25.2K |
|
|
KRON
327
DELISTED
Kronos Bio
KRON
| $205K | 0.08% |
+8,554
| New | +$205K |
|
328
Passage Bio
PASG
$22.8M
| $205K | 0.08% |
+773
| New | +$205K |
|
329
Revolution Medicines
RVMD
$7.57B
| $205K | 0.08% |
6,471
-454
| -7% | -$14.4K |
|
330
Arvinas
ARVN
$575M
| $204K | 0.08% |
2,655
-2,496
| -48% | -$192K |
|
331
Wave Life Sciences
WVE
$1.32B
| $204K | 0.08% |
30,600
-2,003
| -6% | -$13.4K |
|
332
Zymeworks
ZYME
$1.14B
| $204K | 0.08% |
5,894
+56
| +1% | +$1.94K |
|
333
ALX Oncology
ALXO
$65.3M
| $203K | 0.08% |
3,718
-40
| -1% | -$2.18K |
|
334
Cytokinetics
CYTK
$6.34B
| $203K | 0.08% |
10,237
-3,899
| -28% | -$77.3K |
|
335
Mersana Therapeutics
MRSN
$34M
| $203K | 0.08% |
596
+125
| +27% | +$42.6K |
|
336
Syndax Pharmaceuticals
SNDX
$1.47B
| $203K | 0.08% |
11,835
+7
| +0.1% | +$120 |
|
|
TCRR
337
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $203K | 0.08% |
12,379
+1,696
| +16% | +$27.8K |
|
338
Atea Pharmaceuticals
AVIR
$267M
| $202K | 0.08% |
+9,395
| New | +$202K |
|
339
Madrigal Pharmaceuticals
MDGL
$9.65B
| $202K | 0.08% |
2,078
-402
| -16% | -$39.1K |
|
340
Scholar Rock
SRRK
$3.02B
| $202K | 0.08% |
6,975
+718
| +11% | +$20.8K |
|
341
C4 Therapeutics
CCCC
$194M
| $201K | 0.08% |
+5,312
| New | +$201K |
|
342
Nurix Therapeutics
NRIX
$758M
| $201K | 0.08% |
+7,570
| New | +$201K |
|
343
Oric Pharmaceuticals
ORIC
$1.06B
| $201K | 0.08% |
11,349
+2,955
| +35% | +$52.3K |
|
|
HARP
344
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $201K | 0.08% |
1,449
-676
| -32% | -$93.8K |
|
|
ATNX
345
DELISTED
Athenex, Inc. Common Stock
ATNX
| $201K | 0.08% |
2,180
+958
| +78% | +$88.3K |
|
346
AbCellera Biologics
ABCL
$1.26B
| $200K | 0.08% |
+9,111
| New | +$200K |
|
347
Kura Oncology
KURA
$713M
| $200K | 0.08% |
9,572
+2,304
| +32% | +$48.1K |
|
348
Alaunos Therapeutics
TCRT
$4.27M
| $200K | 0.08% |
506
-142
| -22% | -$56.1K |
|
|
GRTS
349
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $200K | 0.08% |
+21,930
| New | +$200K |
|
|
GRCL
350
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $200K | 0.08% |
+15,363
| New | +$200K |
|